| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Internal Medicine, Division of Endocrinology and Metabolism (M.S.R., A.L.B.), and Department of Pediatrics and Communicable Diseases, Division of Endocrinology (M.S.R., C.M.F.), University of Michigan Medical Center; and Department of Veterans Affairs Medical Center (K.V.S.), Ann Arbor, Michigan 48109
Address all correspondence and requests for reprints to: Ariel L. Barkan, M.D., Division of Endocrinology and Metabolism, 3920 Taubman Center, Box 0354, University of Michigan Medical Center, Ann Arbor, Michigan 48109. E-mail: abarkan{at}umich.edu.
The increase in pituitary GH secretion that occurs during mid-late puberty in boys follows an increase in circulating testosterone (T) concentration; the direct mechanism by which this occurs is unknown. We hypothesized that T increases GH secretion during puberty by augmenting hypothalamic output of GHRH. Using constant infusions of a GHRH antagonist, we tested this hypothesis in six early pubertal boys with constitutional delay of growth and adolescence who had a mean chronological age of 14.0 ± 0.3 yr and mean bone age of 11.4 ± 0.2 yr. Blood samples were obtained from subjects every 15 min for 24 h during the overnight infusion of normal saline (20000600 h) and again during the overnight infusion of GHRH antagonist (0.33 µg/kg/h) the following night. Subjects then received transdermal T (5-mg patch) for 12 h nightly and were studied again after 4 wk of treatment. Serum samples were assayed for GH and total ghrelin; the percent suppression of GH during GHRH antagonist infusion was calculated. Morning serum T rose from 0.44 ± 0.09 to 4.43 ± 0.74 µg/liter (P = 0.005). T treatment was associated with a 92.6% increase in mean nocturnal GH secretion area under the curve (830 ± 177 to 1599 ± 340 µg/24 h·liter). Infusion of GHRH-antagonist suppressed mean nocturnal GH area under the curve by 29.1% before T treatment (830 ± 177 to 621 ± 168 µg/24 h·liter), and by 29.4% after T treatment (1599 ± 340 to 1182 ± 249 µg/24 h·liter; P = 0.99). Somatotroph sensitivity to GHRH was tested with 0.1- and 1.0-µg/kg doses of GHRH-44 iv; GH response did not change with regard to T treatment. The mean 24-h concentration of total ghrelin was unchanged with regard to T treatment. In summary, nightly transdermal T administration in six boys with constitutional delay of growth and adolescence increased GH output almost 2-fold, whereas the degree of GH suppressibility by GHRH antagonist remained unchanged. We conclude that the T-associated augmentation of GH secretion during early puberty in boys is unlikely to involve an absolute increase in hypothalamic GHRH output.
This work was supported by USPHS Grants RO-1-DK-38449 (A.L.B.) and MO-1-RR00042 (University of Michigan General Clinical Research Center) and the Department of Veterans Affairs Medical Research Service (A.L.B.).
Abbreviations: AUC, Area under the curve; E2, estradiol; SRIH, somatostatin; T, testosterone.
This article has been cited by other articles:
![]() |
K. J. Mackelvie, G. S. Meneilly, D. Elahi, A. C. K. Wong, S. I. Barr, and J.-P. Chanoine Regulation of Appetite in Lean and Obese Adolescents after Exercise: Role of Acylated and Desacyl Ghrelin J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 648 - 654. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |